

1991 INDEX

A

- Abortion: habitual, and preconception counseling, Mar./Apr. 47
- Abscess: tubo-ovarian, Nov./Dec. 218-219
- Accountability: era of, in health care, Sept./Oct. 156-157
- ACOG
 - publications, Sept./Oct. 158
 - quality assurance indicators, Sept./Oct. 161
 - quality improvement and, Sept./Oct. 157-162
- Adhesions
 - causing chronic pelvic pain, July/Aug. 109-111
 - lysis, in chronic pelvic pain, July/Aug. 128
- Age
 - advanced, maternal, and preconception counseling, Mar./Apr. 45-46
 - maternal, and genetic risk to fetus, Mar./Apr. 51-52
 - paternal, and genetic risk to fetus, Mar./Apr. 52
- AIDS
 - (See also HIV)
 - in women, Nov./Dec. 190
 - incidence, Nov./Dec. 190
- AML, Jan./Feb. 30-31
 - labor characteristics with, Jan./Feb. 31
 - in labor in primigravida (see Labor in primigravida, AML)
- Amniocentesis: chromosomal abnormality at, Mar./Apr. 51
- Anal gonococcal infection, Nov./Dec. 194
- Analgesia: epidural, and labor in primigravida, Jan./Feb. 20
- Anemia: sickle cell, and preconception counseling, Mar./Apr. 59
- Antibody(ies): anticardiolipin, and preconception counseling, Mar./Apr. 58-59
- Anticardiolipin antibodies: and preconception counseling, Mar./Apr. 58-59
- Anticoagulant: lupus, and preconception counseling, Mar./Apr. 58-59
- Antifibrinolytic agents: in dysfunctional uterine bleeding, May/June 91
- Antigen(s): cancer, 125, and dysfunctional uterine bleeding, May/June 84
- Arachidonic acid
 - leukotriene products of, July/Aug. 115
 - prostaglandin and, July/Aug. 115
- Arthritis: rheumatoid, preconception counseling in, Mar./Apr. 58
- Asthma: and preconception counseling, Mar./Apr. 56

B

- Bacterial
 - sexually transmitted diseases, Nov./Dec. 193-208
 - vaginosis (see Vaginosis, bacterial)
- Bartholinitis: chlamydia, Nov./Dec. 205
- Behavioral
 - approach to chronic pelvic pain, July/Aug. 132
 - indices in chronic pelvic pain, July/Aug. 130-131

- Biopsy: cone, and preconception counseling, Mar./Apr. 47
- Birth weight: and labor in primigravida, Jan./Feb. 18-20
- Bleeding
 - menstrual, and prostaglandins, May/June 86
 - uterus (see Uterus, bleeding)
- Bowel: inflammatory disease and preconception counseling, Mar./Apr. 57
- Brain factors: in chronic pelvic pain, July/Aug. 122-126
- Breech: and labor in primigravida, Jan./Feb. 26-27

C

- Cancer antigen 125: and dysfunctional uterine bleeding, May/June 84
- Cardiomyopathy: peripartum, and preconception counseling, Mar./Apr. 60-61
- Cardiovascular disorders: and preconception counseling Mar./Apr. 59-61
- Care
 - appropriateness in obstetrics and gynecology, Sept./Oct. 163-164
 - cost, and health care benefits, Sept./Oct. 153
 - health (see Health care)
 - quality, ACOG publications about, Sept./Oct. 158
- Cell: sickle cell anemia and preconception counseling, Mar./Apr. 59
- Cephalo-pelvic disproportion, Jan./Feb. 18
- Cervicitis, Nov./Dec. 194
- Cervix
 - dilation
 - dystocia and, Jan./Feb. 18
 - after oxytocin in labor, Jan./Feb. 18
 - effacement in primigravida labor, Jan./Feb. 14
 - trauma and preconception counseling, Mar./Apr. 47
- Cesarean section
 - for dystocia, Jan./Feb. 24-25
 - indications for, Jan./Feb. 10, 25
 - AML and, Jan./Feb. 31
- Chancroid, Nov./Dec. 201-203
 - diagnosis, Nov./Dec. 201-202
 - reported cases in U.S., Nov./Dec. 201
 - treatment, Nov./Dec. 202-203
- Chlamydia, Nov./Dec. 204-208
 - bartholinitis, Nov./Dec. 205
 - biology, Nov./Dec. 204-205
 - conjunctivitis in newborn, Nov./Dec. 206
 - culture method for, Nov./Dec. 207-208
 - endocervicitis, Nov./Dec. 205
 - endometritis
 - nonpuerperal, Nov./Dec. 205
 - puerperal, Nov./Dec. 206
 - fetal wastage and, Nov./Dec. 206
 - laboratory studies, Nov./Dec. 207-208
 - in newborn, Nov./Dec. 206
 - pneumonia, in newborn, Nov./Dec. 206-207
 - prevention, Nov./Dec. 208
 - salpingitis, acute, Nov./Dec. 205
 - trachomatis serotypes, Nov./Dec. 204

Chlamydia (*cont.*)

- treatment, Nov./Dec. 208
- urethral syndrome, Nov./Dec. 205
- in women, Nov./Dec. 205-206
- Chromosome abnormality
 - at amniocentesis, Mar./Apr. 51
 - previous child with, and genetic risk to fetus, Mar./Apr. 53
- Cirrhosis: and preconception counseling, Mar./Apr. 58
- Clomiphene: in dysfunctional uterine bleeding, May/June 91
- Cognitive approach: to chronic pelvic pain, July/Aug. 132
- Collagen diseases: and preconception counseling, Mar./Apr. 58
- Cone biopsy: and preconception counseling, Mar./Apr. 47
- Conjunctivitis: chlamydia, in newborn, Nov./Dec. 206
- Consent: informed, Sept./Oct. 170-174
- Corpus luteum: function, May/June 80
- Cost
 - of care and health care benefits, Sept./Oct. 153
 - of pelvic inflammatory disease, Nov./Dec. 214
- Counseling, preconception (*see* Preconception counseling)
- Cystic fibrosis: and genetic risk to fetus, Mar./Apr. 54

D

- Danazol: in dysfunctional uterine bleeding, May/June 91
- Delivery
 - preterm, and preconception counseling, Mar./Apr. 48
 - uterine work required for, Jan./Feb. 11
- Diabetes mellitus: and preconception counseling, Mar./Apr. 54-55
- Diethylstilbestrol exposure: and preconception counseling, Mar./Apr. 46-47
- Donovanosis (*see* Granuloma inguinale)
- Drug(s)
 - abuse, and preconception counseling, Mar./Apr. 48
 - medications and preconception counseling, Mar./Apr. 48-49
- Dystocia
 - birth weight and, Jan./Feb. 19
 - cervical dilation and, Jan./Feb. 18
 - cesarean section for, Jan./Feb. 24-25
 - labor in primigravida and, Jan./Feb. 23-25

E

- Ectopic pregnancy
 - preconception counseling and, Mar./Apr. 47
 - rate in U.S., Nov./Dec. 220
- Effectiveness
 - of health care, Sept./Oct. 153
 - research movement, Sept./Oct. 154-155
- Emotional support: during labor in primigravida, Jan./Feb. 20-21
- Endocervicitis: chlamydia, Nov./Dec. 205
- Endocrine disease: and preconception counseling, Mar./Apr. 54-56
- Endocrinology of endometrium (*see* Endometrium, endocrinology)

- Endometriosis: causing chronic pelvic pain, July/Aug. 111-112
- Endometritis, chlamydia (*see* Chlamydia endometritis)
- Endometrium
 - ablation in dysfunctional uterine bleeding, May/June 91-92
 - cycle and dysfunctional uterine bleeding, May/June 82-85
 - endocrinology of
 - abstract, May/June 75
 - uterine bleeding and, dysfunctional, May/June 83
 - protein, progestogen-associated, and dysfunctional uterine bleeding, May/June 84
 - secretory compounds and dysfunctional uterine bleeding, May/June 83-85
 - secretory products, May/June 83
- Epidural analgesia: in labor in primigravida, Jan./Feb. 20
- Epilepsy: in preconception counseling, Mar./Apr. 56-57
- Ethnic screening: and genetic risk to fetus, Mar./Apr. 53
- Exercise: and preconception counseling, Mar./Apr. 49

F

- Fatty liver: and preconception counseling, Mar./Apr. 57
- Fetus
 - care in labor in gravida, Jan./Feb. 25-27
 - genetic risk to (*see* Genetic risk to fetus)
 - wastage and chlamydia, Nov./Dec. 206
- Fibrosis: cystic, and genetic risk to fetus, Mar./Apr. 54
- Folliculogenic process, May/June 80
- Friedman curve, Jan./Feb. 15

G

- Gastroenterologic causes: of chronic pelvic pain, July/Aug. 117-119
- Gastrointestinal disorders: and preconception counseling, Mar./Apr. 57-58
- Genetic risk to fetus, Mar./Apr. 51-54
 - cystic fibrosis, Mar./Apr. 54
 - ethnic screening, Mar./Apr. 53
 - family history and, Mar./Apr. 52
 - in heart disease, congenital, in family history, Mar./Apr. 53-54
 - maternal age, Mar./Apr. 51-52
 - neural tube defects, Mar./Apr. 53
 - paternal age, Mar./Apr. 52
 - preconception counseling and, Mar./Apr. 51-54
 - in previous child with chromosome abnormality, Mar./Apr. 53
- Genital
 - herpes simplex (*see* Herpes simplex, genital)
 - papillomavirus infection (*see* Papillomavirus infection, genital)
- Genitalia: internal, nerve supply of, July/Aug. 106
- Gonococcal infection
 - anal, Nov./Dec. 194
 - disseminated, Nov./Dec. 194
 - pharyngeal, Nov./Dec. 194
 - reported cases in U.S., Nov./Dec. 193

Gonorrhea, Nov./Dec. 193-196
diagnosis, Nov./Dec. 195
risk factors for, Nov./Dec. 193-194
treatment, Nov./Dec. 195-196

CDC recommendations, Nov./Dec. 195

Granuloma inguinale, Nov./Dec. 203-204
diagnosis, Nov./Dec. 203-204
treatment, Nov./Dec. 204

Gynecology

ACOG guidelines, Sept./Oct. 158
care appropriateness, Sept./Oct. 163-164
clinical indicators in, Sept./Oct. 159
quality improvement in, Sept./Oct. 157-164
(See also Quality improvement)

H

Health care, Sept./Oct. 146-175
benefits and care cost, Sept./Oct. 153
effective procedures, Sept./Oct. 174
effectiveness, Sept./Oct. 153, 174
of procedures, Sept./Oct. 147
quality of life measures in, Sept./Oct. 164-170
efficacy, Sept./Oct. 174
efficiency, Sept./Oct. 174
"efficient," memory device to define, Sept./Oct. 172
efficient procedures, Sept./Oct. 174
era of assessment and accountability, Sept./Oct. 156-157
outcome assessment, Sept./Oct. 147-148
process assessment, Sept./Oct. 147
quality assessment in, Sept./Oct. 152-154
levels for, various, Sept./Oct. 153
quality assurance in, Sept./Oct. 151
quality center for, Sept./Oct. 151
quality improvement in, Sept./Oct. 151
abstract, Sept./Oct. 146
discussion of, Sept./Oct. 152
movement for, Sept./Oct. 151-157
quality of life measures in (see Quality of life measures)
structure assessment, Sept./Oct. 147

Heart disease

congenital, in family history and genetic risk to fetus, Mar./Apr. 53-54

preconception counseling and, Mar./Apr. 60

Hematologic disorders: and preconception counseling, Mar./Apr. 59

Hemorrhage (see Bleeding)

Hepatitis B carrier: and preconception counseling, Mar./Apr. 57-58

Hepatitis B virus infection, Nov./Dec. 192-193
clinical presentation, Nov./Dec. 192
diagnosis, Nov./Dec. 192-193
epidemiology, Nov./Dec. 192
treatment, Nov./Dec. 193

Hepatitis: chronic, and preconception counseling, Mar./Apr. 58

Hepatobiliary disorders: and preconception counseling, Mar./Apr. 57-58

Herpes simplex, genital, Nov./Dec. 187-190
clinical presentation, Nov./Dec. 188

diagnosis, Nov./Dec. 188-189
differential features, Nov./Dec. 188
epidemiology, Nov./Dec. 187
treatment, Nov./Dec. 189-190

HIV, Nov./Dec. 190-192

(See also AIDS)

clinical presentation, Nov./Dec. 190-191
diagnosis, Nov./Dec. 191
epidemiology, Nov./Dec. 190
syphilis and, Nov./Dec. 198
treatment, Nov./Dec. 191-192

Hormone(s)

peptide, and dysfunctional uterine bleeding, May/June 83-85

treatment in dysfunctional uterine bleeding, May/June 90

Human immunodeficiency virus (see HIV)

Hyperprolactinemia: and preconception counseling, Mar./Apr. 56

Hypertension: and preconception counseling, Mar./Apr. 61-62

Hyperthermia: and preconception counseling, Mar./Apr. 48

Hypophysectomy: in dysfunctional uterine bleeding, May/June 91

Hysterectomy

indication list with criteria, Sept./Oct. 163

in pelvic pain, chronic, July/Aug. 128

rates, variation between U.S. and England, Sept./Oct. 156

in uterine bleeding, dysfunctional, May/June 92

Hysteroscopy in unexplained uterine bleeding, May/June 88-89

operative, May/June 89

I

Iliohypogastric nerve, July/Aug. 120

Ilioinguinal nerve, July/Aug. 120

Infertility: pelvic inflammatory disease causing, Nov./Dec. 219

Inflammatory bowel disease: and preconception counseling, Mar./Apr. 57

Informed consent, Sept./Oct. 170-174

Intoxication: water, and oxytocin, Jan./Feb. 23

Intrahepaticcholelithiasis: of pregnancy and preconception counseling, Mar./Apr. 57

K

Kidney

disease and preconception counseling, Mar./Apr. 61-62

transplant and preconception counseling, Mar./Apr. 62

L

Labor in multigravida: vs. labor in primigravida, Jan./Feb. 10-12

Labor in primigravida, Jan./Feb. 5-34
abstract, Jan./Feb. 5

Labor in primigravida (*cont.*)

- AML, Jan./Feb. 30-31
 - cesarean section indications in, Jan./Feb. 31
 - labor characteristics with, Jan./Feb. 31
 - analgesia in, epidural, Jan./Feb. 20
 - birth weight and, Jan./Feb. 18-20
 - breech, Jan./Feb. 26-27
 - cervical effacement in, Jan./Feb. 14
 - definition of labor, Jan./Feb. 12-25
 - diagnosis of labor, Jan./Feb. 13-14
 - duration of labor, Jan./Feb. 30
 - mean, Jan./Feb. 19-20
 - dystocia in, Jan./Feb. 23-25
 - emotional support during, Jan./Feb. 20-21
 - fetus, care of, Jan./Feb. 25-27
 - first stage, Jan./Feb. 16-17
 - latent phase, active management, Jan./Feb. 17
 - management, active, Jan./Feb. 27-31
 - medical components of, Jan./Feb. 29-30
 - multiple pregnancy, Jan./Feb. 27
 - obstetric procedures, Jan./Feb. 10
 - oxytocin in, Jan./Feb. 20, 21-23
 - cervical dilation after, Jan./Feb. 18
 - dosage regimens, Jan./Feb. 21-22
 - side effects, Jan./Feb. 22-23
 - partogram, Jan./Feb. 16
 - preterm, Jan./Feb. 26
 - progress in labor, Jan./Feb. 15-18
 - factors affecting, Jan./Feb. 18-21
 - slow, Jan./Feb. 17-18
 - second stage, Jan./Feb. 17
 - show, the, Jan./Feb. 14
 - uterine rupture in, Jan./Feb. 22-23
 - vs. multigravida, Jan./Feb. 10-12
 - water intoxication and, Jan./Feb. 23
- Laparoscopy
- diagnostic, in chronic pelvic pain, July/Aug. 127-128
 - in pelvic pain, chronic, July/Aug. 108
- Leukotriene products: of arachidonic acid, July/Aug. 115
- Lifestyle: and preconception counseling, Mar./Apr. 48
- Liver: fatty, and preconception counseling, Mar./Apr. 57
- Lung disease: and preconception counseling, Mar./Apr. 56
- Lupus
- anticoagulant and preconception counseling, Mar./Apr. 58-59
 - erythematosus, systemic, and preconception counseling, Mar./Apr. 58
- Lymphogranuloma venereum, Nov./Dec. 200-201
- clinical presentation, Nov./Dec. 200
 - diagnosis, Nov./Dec. 201
 - treatment, Nov./Dec. 201
- Lysis: of adhesions in chronic pelvic pain, July/Aug. 128

M

- Marfan syndrome: and preconception counseling, Mar./Apr. 60
- Marital functioning: in chronic pelvic pain, July/Aug. 132-133
- Medications (*see* Drugs)

- Menstrual bleeding: and prostaglandins, May/June 86
- Menstrual cycle and dysfunctional uterine bleeding, May/June 79-82
 - abstract, May/June 74-75
- Model: for pelvic pain, chronic, July/Aug. 108-109
- Multigravida: labor in, vs. labor in primigravida, Jan./Feb. 10-12
- Multiple pregnancy: and labor in primigravida, Jan./Feb. 27
- Multiple sclerosis: and preconception counseling, Mar./Apr. 57
- Musculoskeletal causes: of chronic pelvic pain, July/Aug. 121
- Myofascial pain, July/Aug. 121-122

N

- Nerve
- entrapment causing chronic pelvic pain, July/Aug. 119-121
 - iliohypogastric, July/Aug. 120
 - ilioinguinal, July/Aug. 120
 - supply of internal genitalia, July/Aug. 106
 - uterosacral, ablation in chronic pelvic pain, July/Aug. 129
- Neural tube defects: and genetic risk to fetus, Mar./Apr. 53
- Neurectomy: presacral, in chronic pelvic pain, July/Aug. 128-129
- Neurologic disorders: and preconception counseling, Mar./Apr. 56-57
- Newborn
- chlamydia, Nov./Dec. 206
 - conjunctivitis, chlamydia, Nov./Dec. 206
 - pneumonia, chlamydia, Nov./Dec. 206-207
- Nutrition: and preconception counseling, Mar./Apr. 49

O

- Obstetric(s)
- ACOG publications and guidelines, Sept./Oct. 158
 - care appropriateness, Sept./Oct. 163-164
 - clinical indicators in, Sept./Oct. 158
 - criteria set, example of, Sept./Oct. 159
 - quality improvement in, Sept./Oct. 157-164
(*See also* Quality improvement)
- Occipito-posterior position: persistent, Jan./Feb. 18
- Outcome(s)
- assessment in health care, Sept./Oct. 147-148
 - effectiveness research movement and, Sept./Oct. 154-155
 - patient outcomes research teams, Sept./Oct. 156
- Ovaries
- functions, biochemical regulators, May/June 82
 - remnant syndrome causing chronic pelvic pain, July/Aug. 114-115
 - tubo-ovarian abscess, Nov./Dec. 218-219
- Oxytocin
- birth weight and, Jan./Feb. 19
 - cervical dilation after, Jan./Feb. 18
 - labor in primigravida and (*see* Labor in primigravida, oxytocin in)

second stage and, Jan./Feb. 20
uterine rupture and, Jan./Feb. 22-23

P

Pain

chronic

central modulation of, July/Aug. 109
peripheral modulation of, July/Aug. 108
spinal cord modulation of, July/Aug. 109
myofascial, July/Aug. 121-122
pelvis (*see* Pelvis, pain)
visceral, July/Aug. 107-108

Papillomavirus, genital human, Nov./Dec. 185-187

clinical presentation, Nov./Dec. 186
diagnosis, Nov./Dec. 186-187
epidemiology, Nov./Dec. 185-186
treatment, Nov./Dec. 187

Pelvis

congestion causing chronic pelvic pain, July/Aug. 112-114

inflammatory disease, Nov./Dec. 194, 214-220

cost, financial, Nov./Dec. 214
diagnosis, Nov./Dec. 216-217
diagnosis, criteria for, Nov./Dec. 216
infertility due to, Nov./Dec. 219
inpatient management, Nov./Dec. 218
microbiology, Nov./Dec. 215-216
microorganism isolation in, Nov./Dec. 216
outpatient management, Nov./Dec. 217
during pregnancy, Nov./Dec. 220
risk factors for, Nov./Dec. 215
sequelae, long-term, Nov./Dec. 219-220
treatment, Nov./Dec. 217-218

pain, chronic, July/Aug. 102-137

abstract, July/Aug. 102
adhesion lysis in, July/Aug. 128
adhesions causing, July/Aug. 109-110
assessment of pain, July/Aug. 129-130
behavioral indices in, July/Aug. 130-131
brain factors in, July/Aug. 122-126
causes of, gastroenterologic, July/Aug. 117-119
causes of, musculoskeletal, July/Aug. 121
causes of, peripheral, July/Aug. 109-122
causes of, peripheral, listing of, July/Aug. 110
causes of, urologic, July/Aug. 119
central factors in, July/Aug. 122-126
cognitive-behavioral approaches in, July/Aug. 132
diagnosis, July/Aug. 126-127
endometriosis causing, July/Aug. 111-112
evaluation of, psychological components of, July/Aug. 129-133
examination in, July/Aug. 126-127
history in, July/Aug. 126
hysterectomy in, July/Aug. 128
laparoscopy for, July/Aug. 108
management, July/Aug. 126-127, 131-132
management, multidisciplinary, July/Aug. 133
management, psychological components of, July/Aug. 129-133
marital functioning in, July/Aug. 132-133
model for, July/Aug. 108

nerve entrapment causing, July/Aug. 119-121
neurectomy in, presacral, July/Aug. 128-129
neuroanatomy of, July/Aug. 105-107
neurophysiology of, July/Aug. 105-107
ovarian remnant syndrome causing, July/Aug. 114-115

pelvic congestion causing, July/Aug. 112-114
relaxation in, July/Aug. 132
salpingo-oophoritis causing, July/Aug. 114
sexual functioning in, July/Aug. 132-133
spinal cord factors in, July/Aug. 122
stress management in, July/Aug. 132
subjective report, July/Aug. 130
surgery of, July/Aug. 127-133
surgery, PREPARE mnemonic, July/Aug. 128
trauma in past, dealing with, July/Aug. 133
uterosacral nerve ablation in, July/Aug. 129
visits 1 through 3, July/Aug. 126-127
without pathology, July/Aug. 126

pain, cyclic, July/Aug. 115-117

Peptide hormones: and dysfunctional uterine bleeding, May/June 83-85

Pharynx: gonococcal infection, Nov./Dec. 194

Phenylketonuria: and preconception counseling, Mar./Apr. 55

PID (*see* Pelvis, inflammatory disease)

Pneumonia: chlamydia, in newborn, Nov./Dec. 206-207

Preconception counseling, Mar./Apr. 42-66

in abortion, habitual, Mar./Apr. 47
abstract, Mar./Apr. 42-43
in anticardiolipin antibodies, Mar./Apr. 58-59
in arthritis, rheumatoid, Mar./Apr. 58
in artificial valves, Mar./Apr. 60
in asthma, Mar./Apr. 56
in bowel disease, inflammatory, Mar./Apr. 57
in cardiomyopathy, peripartum, Mar./Apr. 60-61
in cardiovascular disorders, Mar./Apr. 59-61
in cervical trauma, Mar./Apr. 47
in cirrhosis, Mar./Apr. 58
in collagen disorders, Mar./Apr. 58
cone biopsy, Mar./Apr. 47
in diabetes, Mar./Apr. 54-55
in diethylstilbestrol exposure, Mar./Apr. 46-47
ectopic pregnancy, Mar./Apr. 47
in endocrine disease Mar./Apr. 54-56
in epilepsy, Mar./Apr. 56-57
exercise and, Mar./Apr. 49
in fatty liver, Mar./Apr. 57
in gastrointestinal disorders, Mar./Apr. 57-58
in genetic risk to fetus (*see* Genetic risk to fetus)
in heart disease, Mar./Apr. 60
in hematologic disorders, Mar./Apr. 59
of hepatitis B carrier, Mar./Apr. 57-58
in hepatitis, chronic, Mar./Apr. 58
in hepatobiliary disorders, Mar./Apr. 57-58
hyperprolactinemia and, Mar./Apr. 56
in hypertension, Mar./Apr. 61-62
hyperthermia, Mar./Apr. 48
infection, Mar./Apr. 49-51
in intrahepatic cholelithiasis of pregnancy, Mar./Apr.

Preconception counseling (*cont.*)

- in kidney disease, Mar./Apr. 61-62
 - in kidney transplant, Mar./Apr. 62
 - in lung disease, Mar./Apr. 56
 - in lupus
 - anticoagulant, Mar./Apr. 58-59
 - erythematous, systemic, Mar./Apr. 58
 - in Marfan syndrome, Mar./Apr. 60
 - maternal status, Mar./Apr. 45-51
 - advanced age, Mar./Apr. 45-46
 - lifestyles, Mar./Apr. 48
 - medications, Mar./Apr. 48-49
 - reproductive history, Mar./Apr. 46-48
 - in medical disorders, Mar./Apr. 54-62
 - in metabolic disease, Mar./Apr. 54-56
 - in multiple sclerosis, Mar./Apr. 57
 - in neurologic disorders, Mar./Apr. 56-57
 - nutrition and, Mar./Apr. 49
 - obstetrical complications in history, Mar./Apr. 48
 - paternal status, Mar./Apr. 51
 - phenylketonuria and, Mar./Apr. 55
 - preterm delivery, Mar./Apr. 48
 - in purpura, autoimmune thrombocytopenic, Mar./Apr. 59
 - in rheumatologic disorders, Mar./Apr. 58
 - in sickle cell anemia, Mar./Apr. 59
 - substance abuse, Mar./Apr. 48
 - in thromboembolism, Mar./Apr. 59-60
 - in thyroid disease, Mar./Apr. 56-57
 - in vascular disorders, Mar./Apr. 58
- Pregnancy**
- ectopic (*see* Ectopic pregnancy)
 - intrahepaticcholelithiasis of, and preconception counseling, Mar./Apr. 57
 - multiple, and labor in primigravida, Jan./Feb. 27
 - pelvic inflammatory disease during, Nov./Dec. 220
- Preterm**
- delivery, and preconception counseling, Mar./Apr. 48
 - labor in primigravida, Jan./Feb. 26
- Primigravida labor in (*see* Labor in primigravida)**
- Progestogen-associated endometrial protein: and dysfunctional uterine bleeding, May/June 84**
- Prolactin: in dysfunctional uterine bleeding, May/June 83-84**
- Prostaglandin(s)**
- arachidonic acid and, July/Aug. 115
 - menstrual bleeding and, May/June 86
 - synthesis, May/June 84
 - synthetase inhibitors in dysfunctional uterine bleeding, May/June 90-91
- Prostanoids**
- actions of, May/June 85
 - in dysfunctional uterine bleeding, May/June 84-85
- Protein: endometrial, progestogen-associated, and dysfunctional uterine bleeding, May/June 84**
- Purpura: autoimmune thrombocytopenic, and preconception counseling, Mar./Apr. 59**

Q

Quality

- assessment in health care, Sept./Oct. 152-154

- levels for, various, Sept./Oct. 153
- assurance in health care, Sept./Oct. 151
- assurance indicators of ACOG, Sept./Oct. 161
- of care, ACOG publications about, Sept./Oct. 158
- center for health care, Sept./Oct. 151
- improvement
 - ACOG and, Sept./Oct. 157-162
 - annualized rates of published articles, Sept./Oct. 157
 - clinical indicators validation, Sept./Oct. 160-162
 - criteria sets validation, Sept./Oct. 162-163
 - in health care (*see* Health care, quality improvement in)
 - in obstetrics and gynecology, Sept./Oct. 157-164
- lack of variation as measure of, Sept./Oct. 155-156
- of life measures, Sept./Oct. 164-170
 - barriers to use of, Sept./Oct. 169-170
 - comparisons of, Sept./Oct. 170
 - generalizability, Sept./Oct. 168
 - generic vs. specific, Sept./Oct. 168
 - interpretation, Sept./Oct. 168-169
 - issues specific to, Sept./Oct. 168-169
 - psychometric properties, Sept./Oct. 165-168
 - purpose, Sept./Oct. 165
 - reliability, Sept./Oct. 165-166
 - summary of selected properties and content, Sept./Oct. 166-167
 - validity, Sept./Oct. 166-168
 - validity, construct, Sept./Oct. 167-168
 - validity, content, Sept./Oct. 167
 - validity, criterion, Sept./Oct. 167
 - validity, discriminate, Sept./Oct. 168

R

- Relaxin: in dysfunctional uterine bleeding, May/June 84**
- Research**
- effectiveness research movement, Sept./Oct. 154-155
 - patient outcomes research teams, Sept./Oct. 156
- Rheumatic heart disease: and preconception counseling, Mar./Apr. 60**
- Rheumatoid arthritis: preconception counseling in, Mar./Apr. 58**
- Rheumatologic disorders: and preconception counseling, Mar./Apr. 58**
- Rupture: of uterus and oxytocin, Jan./Feb. 22-23**

S

- Salpingitis: acute, chlamydia, Nov./Dec. 205**
- Salpingo-oophoritis: causing chronic pelvic pain, July/Aug. 114**
- Sclerosis: multiple, and preconception counseling, Mar./Apr. 57**
- Sexual functioning: in chronic pelvic pain, July/Aug. 132-133**
- Sexually transmitted diseases, Nov./Dec. 118-226**
- abstract, Nov./Dec. 181
 - bacterial, Nov./Dec. 193-208
 - viral, Nov./Dec. 185-193
 - syndromes, Nov./Dec. 208-220

Sickle cell anemia: and preconception counseling, Mar./Apr. 59

Spine, cord
factors in chronic pelvic pain, July/Aug. 122
modulation of chronic pain, July/Aug. 109

Stress management: in chronic pelvic pain, July/Aug. 132

Substance abuse: and preconception counseling, Mar./Apr. 48

Syphilis, Nov./Dec. 196-200
clinical manifestations, Nov./Dec. 196-197
congenital, Nov./Dec. 197
diagnosis, Nov./Dec. 197-198
epidemiology, Nov./Dec. 196
HIV and, Nov./Dec. 198
reported cases in U.S., Nov./Dec. 196
treatment, Nov./Dec. 198-200
CDC recommendations, Nov./Dec. 199

T

Thrombocytopenic purpura: autoimmune, and preconception counseling, Mar./Apr. 59

Thromboembolism: and preconception counseling, Mar./Apr. 59-60

Thyroid disease: and preconception counseling, Mar./Apr. 55-56

Transplantation: kidney, and preconception counseling, Mar./Apr. 62

Tubo-ovarian abscess, Nov./Dec. 218-219

U

Urethral syndrome: chlamydia, Nov./Dec. 205

Urologic causes: of chronic pelvic pain, July/Aug. 119

Uterosacral nerve ablation: in chronic pelvic pain, July/Aug. 129

Uterus
bleeding, dysfunctional, May/June 73-96
abstract, May/June 73-77
antifibrinolytic agents in, May/June 91
cancer antigen 125 in, May/June 84
chart of, May/June 87
clomiphene in, May/June 91
danazol in, May/June 91
diagnosis, May/June 86-89
diagnosis, abstract, May/June 76-77
endometrial ablation techniques in, May/June 91-92
endometrial cycle in, May/June 82-85
endometrial endocrinology in, May/June 83
endometrial endocrinology in, abstract, May/June 75
endometrial secretory compounds in, May/June 83-85
hormonal treatment, May/June 90
hypophysectomy in, medical, May/June 91

hysterectomy in, May/June 92

hysteroscopy in unexplained uterine bleeding, May/June 88-89

hysteroscopy in unexplained uterine bleeding, operative, May/June 89

menstrual cycle in, May/June 79-82

menstrual cycle in, abstract, May/June 74-75

pathogenesis, May/June 85-86

pathogenesis, abstract, May/June 76

peptide hormones in, May/June 83-85

progesterone-associated endometrial protein in, May/June 84

prolactin in, May/June 83-84

prostaglandin synthetase inhibitors in, May/June 90-91

prostaglandins and menstrual bleeding, May/June 86

prostanoids in, May/June 84-85

relaxin in, May/June 84

treatment, May/June 89-92

treatment, abstract, May/June 77

treatment, long-term, May/June 90-92

treatment, long-term, abstract, May/June 77

treatment, urgent, May/June 89-90

treatment, urgent, abstract, May/June 77

uterine contracting agents in, May/June 91

contracting agents in dysfunctional uterine bleeding, May/June 91

contraction tracing, Jan./Feb. 15

rupture, and oxytocin, Jan./Feb. 22-23

work required for delivery, Jan./Feb. 11

V

Vaginosis, bacterial, Nov./Dec. 208-214
complications, associated, Nov./Dec. 212-213
diagnosis, Nov./Dec. 210-212
microbiology, Nov./Dec. 208-209
pathophysiology, Nov./Dec. 210
treatment, Nov./Dec. 213-214

Valve: artificial, and preconception counseling, Mar./Apr. 60

Vessels: disease and preconception counseling, Mar./Apr. 58

Viruses
hepatitis (see Hepatitis B)
herpes simplex (see Herpes simplex)
human immunodeficiency (see HIV)
papillomavirus (see Papillomavirus)
sexually transmitted diseases due to, Nov./Dec. 185-193

Visceral pain, July/Aug. 107-108

W

Water intoxication: and oxytocin, Jan./Feb. 23

Weight: birth, and labor in primigravida, Jan./Feb. 18-20